Reviva pharmaceuticals holdings, inc. receives fda may proceed letter for pivotal phase 3 clinical trial and long-term safety trial evaluating brilaroxazine for the treatment of schizophrenia

- brilaroxazine is a novel serotonin and dopamine receptor modulator currently being developed for diseases with dysfunctional serotonin signaling including neuropsychiatric and pulmonary indications -

RVPH Ratings Summary

RVPH Quant Ranking